ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 25, 2023 -- For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct. 20 in The Lancet. The research was published to coincide with the annual meeting of the European Society for Medical Oncology, held from Oct. 20 to 24 in Madrid.
Yelena Y. Janjigian, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a randomized trial involving adult patients with locally advanced or metastatic HER2-positive gastroesophageal junction adenocarcinoma without previous first-line treatment from 168 medical centers in 20 countries. Participants were randomly assigned to intravenous pembrolizumab 200 mg or placebo (350 and 348, respectively), both combined with standard chemotherapy plus trastuzumab.
The researchers found that at the third interim analysis, 82 and 88 percent of patients in the pembrolizumab and placebo groups, respectively, had discontinued treatment, mainly due to disease progression. Median progression-free survival was 10.0 and 8.1 months in the pembrolizumab and placebo groups, respectively, at the second interim analysis (median follow-up, 28.3 and 28.5 months; hazard ratio, 0.72; 95 percent confidence interval, 0.60 to 0.87). Median overall survival was not significantly different between the groups (20.0 and 16.9 months, respectively; hazard ratio, 0.87; 95 percent confidence interval, 0.72 to 1.06). Median progression-free survival was 10.0 and 8.1 months, respectively, at the third interim analysis (median follow-up, 38.4 and 38.6 months; hazard ratio, 0.73; 95 percent confidence interval, 0.61 to 0.87), and median overall survival was 20.0 and 16.8 months, respectively (hazard ratio, 0.84; 95 percent confidence interval, 0.70 to 1.01), which did not meet the prespecified criteria for significance.
"The final overall survival analysis is needed to establish the long-term therapeutic effect of this regimen," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
Living Outside of Comprehensive Cancer Center Catchment Area Tied to Later-Stage Diagnosis
TUESDAY, May 28, 2024 -- Disadvantaged populations and those living outside of a comprehensive cancer center's main catchment area have higher odds of receiving a diagnosis of...
Disparities Seen in Cancer Treatment Delivery at Minority-Serving Hospitals
TUESDAY, May 28, 2024 -- There are systemic disparities in definitive cancer treatment delivery at minority-serving hospitals (MSHs) versus non-MSHs, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.